Lichuan Liu

发表

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.

Dolores Diaz, Jianping Yin, Michael Burkard, 2016, Journal of medicinal chemistry.

Assessment of OATP transporter‐mediated drug–drug interaction using physiologically‐based pharmacokinetic (PBPK) modeling – a case example

Yuan Chen, J. Mao, E. Choo, 2018, Biopharmaceutics & drug disposition.

Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.

C. Ly, S. Sideris, S. Malek, 2011, Journal of medicinal chemistry.

Investigations into the Mechanisms of Pyridine Ring Cleavage in Vismodegib

J. Lyssikatos, H. Wong, C. Hop, 2014, Drug Metabolism and Disposition.

A Novel Reaction Mediated by Human Aldehyde Oxidase: Amide Hydrolysis of GDC-0834

Jeffrey P. Jones, Donald S Kirkpatrick, Jasleen K Sodhi, 2015, Drug Metabolism and Disposition.

Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.

Adam R. Johnson, C. Eigenbrot, J. Lubach, 2016, Bioorganic & medicinal chemistry letters.

Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase Inhibitor

John C. Davis, P. Kuebler, J. Lubach, 2011, Drug Metabolism and Disposition.

Practical strategies when using a stable isotope labeled microtracer for absolute bioavailability assessment: A case study of a high oral dose clinical candidate GDC‐0810

E. Choo, Kelly Zhang, Buyun Chen, 2018, Journal of pharmaceutical and biomedical analysis.

ET-1 and TNF-alpha in HPS: analysis in prehepatic portal hypertension and biliary and nonbiliary cirrhosis in rats.

M. Fallon, Liping Tang, Lichuan Liu, 2004, American journal of physiology. Gastrointestinal and liver physiology.

Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.

C. Ly, S. Sideris, S. Malek, 2012, Journal of medicinal chemistry.

GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study

Kenta Yoshida, S. Sahasranaman, Buyun Chen, 2019, Drug Metabolism and Disposition.

Vectorial Transport of Enalapril by Oatp 1 a 1 / Mrp 2 and OATP 1 B 1 and OATP 1 B 3 / MRP 2 in Rat and Human Livers

Y. Sugiyama, D. Keppler, K. Pang, 2006 .

Vectorial Transport of Enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in Rat and Human Livers

Y. Sugiyama, D. Keppler, K. Pang, 2006, Journal of Pharmacology and Experimental Therapeutics.

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

J. Byrd, R. Advani, I. Flinn, 2019, Oncotarget.

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

J. Byrd, R. Advani, I. Flinn, 2018, Oncotarget.

Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects

S. Girish, S. Sahasranaman, Buyun Chen, 2018, Pharmaceutical Research.

Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.

Adam R. Johnson, Z. Modrušan, J. DeVoss, 2017, JCI insight.

Vascular Binding, Blood Flow, Transporter, and Enzyme Interactions on the Processing of Digoxin in Rat Liver

P. Novikoff, A. Wolkoff, K. Pang, 2005, Journal of Pharmacology and Experimental Therapeutics.

The role of endothelin‐1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat

W. Grizzle, M. Fallon, Liping Tang, 2004, Hepatology.

Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome.

W. Grizzle, M. Fallon, Liping Tang, 2003, Journal of hepatology.

A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Sandra M. Sanabria-Bohórquez, P. LoRusso, J. Soria, 2016, Clinical Cancer Research.

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Adam R. Johnson, Lisa L. Smith, J. Byrd, 2018, Blood.

Bruton’s Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats

Adam R. Johnson, M. Hedehus, R. Carano, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Novel Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor

P. Kuebler, J. Lubach, H. Wong, 2011 .

Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0834 and its metabolite in human plasma using semi-automated 96-well protein precipitation.

H. Wong, C. Hop, Y. Shin, 2012, Biomedical chromatography : BMC.

Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid – Case Study of GDC-0810

W. Jia, K. Nagapudi, Lichuan Liu, 2018, Pharmaceutical Research.

Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studies

E. O'Mara, M. Rogge, D. Heald, 2016, Journal of clinical pharmacology.

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.

Adam R. Johnson, BinQing Wei, C. Eigenbrot, 2018, Journal of medicinal chemistry.

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties

Adam R. Johnson, C. Eigenbrot, J. Lubach, 2017, ACS medicinal chemistry letters.

Simple methodology to estimate bioavailability in early clinical studies: theory and reality

BinQing Wei, Xingrong Liu, Lichuan Liu, 2017 .

Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.

Adam R. Johnson, C. Eigenbrot, J. Lubach, 2020, ACS medicinal chemistry letters.

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

Andy Z. X. Zhu, Yuan Chen, E. Schuck, 2019, CPT: pharmacometrics & systems pharmacology.

An integrated approach to model hepatic drug clearance.

K. Pang, Lichuan Liu, K Sandy Pang, 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Investigation of the rat model for preclinical evaluation of pH-dependent oral absorption in humans.

J. Lubach, H. Wong, Lichuan Liu, 2013, Molecular pharmaceutics.

Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model

Saroja Ramanujan, Kapil Gadkar, Daniel C. Kirouac, 2017, npj Systems Biology and Applications.

Transporters, enzymes, and enalapril removal in a rat (CC531-induced) liver metastatic model.

K. Pang, Lichuan Liu, Huadong Sun, 2007, American journal of physiology. Gastrointestinal and liver physiology.

Increased Estrogen Sulfation of Estradiol 17β-D-Glucuronide in Metastatic Tumor Rat Livers

K. Pang, Lichuan Liu, Huadong Sun, 2006, Journal of Pharmacology and Experimental Therapeutics.

Role of Haptoglobin on the Uptake of Native and β-Chain [Trimesoyl-(Lys82)β-(Lys82)β] Cross-Linked Human Hemoglobins in Isolated Perfused Rat Livers

K. Pang, E. Chow, R. Kluger, 2008, Drug Metabolism and Disposition.

Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.

S. Hymowitz, J. Lubach, K. Reif, 2015, Bioorganic & medicinal chemistry letters.

SAHA Enhances Synaptic Function and Plasticity In Vitro but Has Limited Brain Availability In Vivo and Does Not Impact Cognition

Kimberly Scearce-Levie, Dani Brunner, Qiang Zhou, 2013, PloS one.

Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR).

S. Sideris, L. Friedman, S. Malek, 2013, Journal of medicinal chemistry.

Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.

M. Belvin, C. Ly, S. Sideris, 2013, ACS medicinal chemistry letters.

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects

Jing Zhang, Lichuan Liu, Yuancheng Chen, 2022, Frontiers in Pharmacology.

Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects

J. Ware, E. Choo, Kenta Yoshida, 2018, Journal of clinical pharmacology.

THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING

K. Pang, Lichuan Liu, K Sandy Pang, 2005, Drug Metabolism and Disposition.

Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy

K. Reif, H. Wong, H. Rong, 2011, Journal of Pharmacology and Experimental Therapeutics.

Preliminary results: exploring the interactions of quantum dots with whole blood components

Hans C. Fischer, Eliseo Papa, Lichuan Liu, 2005, Photonics North.

Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model

K. Gadkar, D. Kirouac, S. Ramanujan, 2017, npj Systems Biology and Applications.

Exposure-Effect Relationships in Established Rat Adjuvant-Induced and Collagen-Induced Arthritis: A Translational Pharmacokinetic-Pharmacodynamic Analysis

W. Ouyang, H. Wong, C. Hop, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer

E. Winer, S. Loi, A. Bardia, 2020, Poster Spotlight Session Abstracts.

Identification of a Discrete Diglucuronide of GDC-0810 in Human Plasma after Oral Administration.

E. Choo, J. Kenny, Lichuan Liu, 2023, Drug Metabolism And Disposition.

1 Identification of a Discrete Diglucuronide of GDC-0810 in Human Plasma after Oral Administration

E. Choo, J. Kenny, Lichuan Liu, 2023 .

Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development

S. Gould, M. Belvin, Peter Yin, 2014 .

Clinical responses to ERK inhibitor (GDC-0994) treatment combinations predicted using a Quantitative Systems Pharmacology model of MAPK signaling in BRAF(V600E)-mutant colorectal cancer

K. Gadkar, D. Kirouac, S. Ramanujan, 2016 .

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Adam R. Johnson, Lisa L. Smith, J. Byrd, 2018, Blood.

A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Sandra M. Sanabria-Bohórquez, P. LoRusso, J. Soria, 2019, Clinical Cancer Research.